Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

302 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rituximab addition to chemotherapy in real world patients with chronic lymphocytic leukemia: effective in first line but indication of lack of efficacy in subsequent lines of therapy.
van der Straten L, Dinmohamed AG, Westerweel PE, Langerak AW, Riedl J, Doorduijn JK, Kater AP, Levin MD. van der Straten L, et al. Among authors: levin md. Leuk Lymphoma. 2018 Nov;59(11):2757-2761. doi: 10.1080/10428194.2018.1452215. Epub 2018 Apr 4. Leuk Lymphoma. 2018. PMID: 29616852 No abstract available.
Prognosis of IGLV3-21R110 chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis.
Hengeveld PJ, Veelken H, van Bergen CAM, Quinten E, Vervoordeldonk MYL, Ismailzada W, Barendse RS, Dubois JMN, van Oers MHJ, Geisler CH, Kater AP, Westerweel PE, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: levin md. Leukemia. 2023 Sep;37(9):1929-1932. doi: 10.1038/s41375-023-01975-0. Epub 2023 Jul 21. Leukemia. 2023. PMID: 37479761 Free PMC article. No abstract available.
Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110.
Hengeveld PJ, Ertem YE, Dubois JMN, Mellink CHM, van der Kevie-Kersemaekers AM, Evers LM, Heezen K, Kolijn PM, Mook ORF, Motazacker MM, Nasserinejad K, Kersting S, Westerweel PE, Niemann CU, Kater AP, Langerak AW, Levin MD. Hengeveld PJ, et al. Among authors: levin md. Leukemia. 2022 Jul;36(7):1935-1938. doi: 10.1038/s41375-022-01600-6. Epub 2022 May 18. Leukemia. 2022. PMID: 35585140 No abstract available.
Detecting measurable residual disease beyond 10-4 by an IGHV leader-based NGS approach improves prognostic stratification in CLL.
Hengeveld PJ, van der Klift MY, Kolijn PM, Davi F, Kavelaars FG, de Jonge E, Robrecht S, Assmann JLJC, van der Straten L, Ritgen M, Westerweel PE, Fischer K, Goede V, Hallek M, Levin MD, Langerak AW. Hengeveld PJ, et al. Among authors: levin md. Blood. 2023 Feb 2;141(5):519-528. doi: 10.1182/blood.2022017411. Blood. 2023. PMID: 36084320 Free article.
High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL.
Hengeveld PJ, Kolijn PM, Demmers JAA, Doff W, Dubois JMN, Rijken M, Assmann JLJC, van der Straten L, Boiten HJ, Gussinklo KJ, Valk PJM, Faber LM, Westerweel PE, Kater AP, Levin MD, Langerak AW. Hengeveld PJ, et al. Among authors: levin md. Hemasphere. 2023 Sep 15;7(10):e951. doi: 10.1097/HS9.0000000000000951. eCollection 2023 Oct. Hemasphere. 2023. PMID: 37731707 Free PMC article.
Blood cell counts and lymphocyte subsets of patients admitted during the COVID-19 pandemic: a prospective cohort study.
Hengeveld PJ, Khader AO, de Bruin LHA, Geelen IGP, van Baalen EA, Jansen E, Bouwer NI, Balak Ö, Riedl JA, Langerak AW, Westerweel PE, Levin MD. Hengeveld PJ, et al. Among authors: levin md. Br J Haematol. 2020 Aug;190(4):e201-e204. doi: 10.1111/bjh.16983. Epub 2020 Jul 28. Br J Haematol. 2020. PMID: 32652585 Free PMC article. Clinical Trial. No abstract available.
302 results